ovarian cancer iii
DESCRIPTION
Ovarian Cancer III. The Patient. 病歷號碼: 0004842134 姓名:張林素真 身分證號: G201044041 床號: 53603 出生日期: 043/01/02 性別:女 入院日期: 094/05/06 年齡: 51. Chief Complaint. Fullness of abdomen sensation. History or Present Illness. Noted abdominal distention for about one month. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/1.jpg)
Ovarian Cancer IIIOvarian Cancer III
![Page 2: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/2.jpg)
The PatientThe Patient
病歷號碼:病歷號碼: 00048421340004842134姓名:張林素真姓名:張林素真身分證號:身分證號: G201044041G201044041床號:床號: 5360353603出生日期:出生日期: 043/01/02043/01/02性別:女性別:女入院日期:入院日期: 094/05/06094/05/06年齡:年齡: 5151
![Page 3: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/3.jpg)
Chief ComplaintChief Complaint
Fullness of abdomen sensationFullness of abdomen sensation
![Page 4: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/4.jpg)
History or Present IllnessHistory or Present Illness
Noted abdominal distention for about one Noted abdominal distention for about one month. month. She also noted frequency of urinationShe also noted frequency of urinationAssuming that the feeling of fullness of abAssuming that the feeling of fullness of abdomen was due to IUD (since 1997), she vdomen was due to IUD (since 1997), she visited Dr. Chang's OPD and requested reisited Dr. Chang's OPD and requested removal of the IUDmoval of the IUDShe underwent an abdominal ultrasound wShe underwent an abdominal ultrasound which revealed hich revealed bilateral ovarian tumor and abilateral ovarian tumor and ascitesscites
![Page 5: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/5.jpg)
UltrasoundUltrasound
![Page 6: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/6.jpg)
![Page 7: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/7.jpg)
![Page 8: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/8.jpg)
![Page 9: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/9.jpg)
Continued HPIContinued HPI
CT scan and was arranged to evaluate thCT scan and was arranged to evaluate the extent of the disease.e extent of the disease. CT, done on 5/4, showed a CT, done on 5/4, showed a 6.7x3.4 cm solid mass over right adnexa6.7x3.4 cm solid mass over right adnexa4cm soft tissue shadow over left adnexa4cm soft tissue shadow over left adnexaMassive ascitesMassive ascitesPeritoneal seedingPeritoneal seeding2 cm liver tumor2 cm liver tumor
![Page 10: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/10.jpg)
CTCT
![Page 11: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/11.jpg)
![Page 12: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/12.jpg)
![Page 13: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/13.jpg)
![Page 14: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/14.jpg)
Continued HPIContinued HPI
Tumor markers were also determined.Tumor markers were also determined.
Serum CA125 = 2288 U/ml Serum CA125 = 2288 U/ml
Serum CEA = 0.5 ng/ml Serum CEA = 0.5 ng/ml
Diagnosis: Ovarian malignancyDiagnosis: Ovarian malignancy
She was advised surgery. Patient consentShe was advised surgery. Patient consented. ed.
Therefore, she was admitted for further maTherefore, she was admitted for further management.nagement.
![Page 15: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/15.jpg)
Past HistoryPast History
1.Asthma for 10+ years1.Asthma for 10+ years
2.Cigarette smoking: Nil; Alcoholic 2.Cigarette smoking: Nil; Alcoholic
drinking: Nildrinking: Nil
3.Previous op. history: Nil3.Previous op. history: Nil
4.allergy: nil4.allergy: nil
![Page 16: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/16.jpg)
Gynecology HistoryGynecology History
G3P3, menopause at 48 y/oG3P3, menopause at 48 y/o
IUD was inserted in 1997 and removed IUD was inserted in 1997 and removed on 2005/5/on 2005/5/
![Page 17: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/17.jpg)
Physical ExamPhysical Exam
Vital sign: stableVital sign: stableHEENT: pink conjunctiva, anicteric sclera, no lyHEENT: pink conjunctiva, anicteric sclera, no lymphadenopathymphadenopathyChest: clear breath soundsChest: clear breath soundsHeart:RHBHeart:RHBAbd: soft, distended, AC 85 cmAbd: soft, distended, AC 85 cm normoactive bowel soundnormoactive bowel sound shifting dullness: (+)shifting dullness: (+) (+) direct tenderness(+) direct tendernessExtremities: no pitting edemaExtremities: no pitting edema
![Page 18: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/18.jpg)
Pelvic ExamPelvic Exam
Uterus non-palpableUterus non-palpable
Bilateral adnexa palpable , enlarged, solidBilateral adnexa palpable , enlarged, solid
Vaginal discharge minimalVaginal discharge minimal
Cervix (-) erosionsCervix (-) erosions
![Page 19: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/19.jpg)
LaboratoryLaboratory
94-05-0694-05-06Hb12.6 Ht38.6 RBC4.20 WBC6.57 NeHb12.6 Ht38.6 RBC4.20 WBC6.57 Neut. Seg53.9 Lympho S.32.9 Mono.10.8 Eut. Seg53.9 Lympho S.32.9 Mono.10.8 Eos.2.1 Baso.0.3 MCV91.9 MCH30.0 Mos.2.1 Baso.0.3 MCV91.9 MCH30.0 MCHC32.6 PLT.283 PT.11.8 PT. control11.CHC32.6 PLT.283 PT.11.8 PT. control11.4 INR1.08 P.T.T.26.8 P.T.T. control30.6 4 INR1.08 P.T.T.26.8 P.T.T. control30.6 94-05-0694-05-06Na140meq/L Na140meq/L K2.9meq/L(L) Ca8.1mg/dl(L)K2.9meq/L(L) Ca8.1mg/dl(L) Cl107meq/L Cl107meq/L Glu.149mg/dl(H)Glu.149mg/dl(H) B.U.N14mg/ B.U.N14mg/dl G.O.T.24I.U./L G.P.T.17I.U./L Cr.1.1mdl G.O.T.24I.U./L G.P.T.17I.U./L Cr.1.1mg/dl g/dl
![Page 20: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/20.jpg)
Course in the WardCourse in the Ward
94.5.6: She was admitted and prepared for 94.5.6: She was admitted and prepared for surgerysurgery
94.5.7: Underwent surgery: laparotomy94.5.7: Underwent surgery: laparotomy
![Page 21: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/21.jpg)
OP FindingsOP FindingsBilateral ovarian tumor with papillary Bilateral ovarian tumor with papillary lesionslesions(+) tumor seeding on the rectum, uterus (+) tumor seeding on the rectum, uterus and bilateral infundibulopelvic ligamentand bilateral infundibulopelvic ligamentAscites of 1300 cc (20 cc sent for cytology Ascites of 1300 cc (20 cc sent for cytology exam)exam)(+) Omental cake(+) Omental cake(+) Tumor on omentum invade the (+) Tumor on omentum invade the superficial lining of the transverse colonsuperficial lining of the transverse colonEstimated blood loss 300 ccEstimated blood loss 300 cc
![Page 22: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/22.jpg)
![Page 23: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/23.jpg)
![Page 24: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/24.jpg)
![Page 25: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/25.jpg)
![Page 26: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/26.jpg)
![Page 27: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/27.jpg)
![Page 28: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/28.jpg)
![Page 29: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/29.jpg)
Surgical procedureSurgical procedure
Optimal Debulking Surgery:Optimal Debulking Surgery:
ATH + BSOATH + BSO
OmentectomyOmentectomy
Bilateral Pelvic Lymph Node DissectionBilateral Pelvic Lymph Node Dissection
![Page 30: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/30.jpg)
Final DiagnosisFinal Diagnosis
Ovarian Cancer IIIcOvarian Cancer IIIc
![Page 31: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/31.jpg)
REVIEWREVIEW
![Page 32: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/32.jpg)
Ovarian Cancer StagingOvarian Cancer StagingStage IStage I - Growth of tumor limited to the ovaries - Growth of tumor limited to the ovaries Stage IIStage II - Growth of tumor in one or both ovaries - Growth of tumor in one or both ovaries Stage IIIStage III - Tumor involving one or both ovaries with - Tumor involving one or both ovaries with peritoneal implants outside the pelvis and/or positive peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal lymph nodes. Superficial liver retroperitoneal or inguinal lymph nodes. Superficial liver metastasis equals stage III. metastasis equals stage III. Stage IVStage IV - Growth involving one or both ovaries with - Growth involving one or both ovaries with distant metastases. If pleural effusion is present there distant metastases. If pleural effusion is present there must be positive cytology to allot a case to stage IV. must be positive cytology to allot a case to stage IV. Tumor spread inside the liver, equals stage IV. Tumor spread inside the liver, equals stage IV. Recurrent/RefractoryRecurrent/Refractory - Recurrence means that the - Recurrence means that the tumor has returned after initial therapy. Refractory tumor has returned after initial therapy. Refractory means that the tumor fails to respond to initial treatment.means that the tumor fails to respond to initial treatment.
![Page 33: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/33.jpg)
Ovarian Cancer StagingOvarian Cancer Staging
Stage IIIStage III Tumor involving one or both ovaries with peritoneal implant Tumor involving one or both ovaries with peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal nodes. s outside the pelvis and/or positive retroperitoneal or inguinal nodes. Superficial liver metastasis equals Stage III. Tumor is limited to the Superficial liver metastasis equals Stage III. Tumor is limited to the true pelvis but with histologically proven malignant extension to smaltrue pelvis but with histologically proven malignant extension to small bowel or omentrum.l bowel or omentrum.
IIIAIIIA Tumor grossly limited to the true pelvis with negative node Tumor grossly limited to the true pelvis with negative nodes but with histologically confirmed microscopic seeding of abds but with histologically confirmed microscopic seeding of abdominal peritoneal surfacesominal peritoneal surfaces
IIIBIIIB Tumor of one or both ovaries with histologically confirmed Tumor of one or both ovaries with histologically confirmed implants of abdominal peritoneal surfaces, none exceeding 2 cimplants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter; nodes are negativem in diameter; nodes are negative
IIIC IIIC Abdominal implants greater than 2 cm in diameter and/or p Abdominal implants greater than 2 cm in diameter and/or positive retroperitoneal or inguinal nodes.ositive retroperitoneal or inguinal nodes.
![Page 34: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/34.jpg)
Treatment of Stage IIITreatment of Stage III
SurgerySurgery has been used as a has been used as a therapeutictherapeutic modalitmodality and also to adequately y and also to adequately stage the disease.stage the disease. Surgery should include Surgery should include total abdominal hysterectotal abdominal hysterectomy and bilateral salpingo-oophorectomy with otomy and bilateral salpingo-oophorectomy with omentectomy and debulkingmentectomy and debulking of as much gross tu of as much gross tumor as can safely be performed. mor as can safely be performed. The The volume of disease leftvolume of disease left at the completion of t at the completion of the primary surgical procedure is related to he primary surgical procedure is related to patiepatient survivalnt survival
![Page 35: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/35.jpg)
Optimal vs. Suboptimal CytoreductiOptimal vs. Suboptimal Cytoreductionon
A literature review showed that patients with A literature review showed that patients with optioptimal cytoreduction had median survival of 39 momal cytoreduction had median survival of 39 monthsnths compared with survival of only compared with survival of only 17 months in 17 months in patients with suboptimal residual diseasepatients with suboptimal residual disease
Hoskins WJ: Surgical staging and cytoreductive Hoskins WJ: Surgical staging and cytoreductive surgery of epithelial ovarian cancer. surgery of epithelial ovarian cancer. CancerCancer 71 71 (4 Suppl): 1534-40, 1993. (4 Suppl): 1534-40, 1993.
![Page 36: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/36.jpg)
INTRAPERITONEAL REGIMENS INTRAPERITONEAL REGIMENS The use of The use of IP cisplatinIP cisplatin as part of the initial up-front a as part of the initial up-front approach in stage III optimally-debulked ovarian cancpproach in stage III optimally-debulked ovarian cancer is supported by the results of 3 randomized clinicer is supported by the results of 3 randomized clinical trials. al trials.
In all 3 studies In all 3 studies superior progression-free survivalsuperior progression-free survival wa was documented favoring IP, and in the 2 fully reported s documented favoring IP, and in the 2 fully reported to date, the to date, the overall survival was also significantly betoverall survival was also significantly betterter in the IP. in the IP.
Alberts DS, Markman M, Armstrong D, et al.: IntraperAlberts DS, Markman M, Armstrong D, et al.: Intraperitoneal therapy for stage III ovarian cancer: a therapy itoneal therapy for stage III ovarian cancer: a therapy whose time has come! whose time has come! J Clin OncolJ Clin Oncol 20 (19): 3944-6, 2 20 (19): 3944-6, 2002 002
IP therapy has not been routinely adopted, in part beIP therapy has not been routinely adopted, in part because of issues relating to cause of issues relating to greater toxicity and incongreater toxicity and inconvenience venience
![Page 37: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/37.jpg)
IP ChemotherapyIP Chemotherapy
This study has demonstrated the feasibility, modThis study has demonstrated the feasibility, moderate toxicity and efficacy of first-line intraperitonerate toxicity and efficacy of first-line intraperitoneal eal paclitaxel-cisplatin chemotherapy.paclitaxel-cisplatin chemotherapy.
Zylberberg B, Dormont D, Madelenat P, Darai E.Zylberberg B, Dormont D, Madelenat P, Darai E.First-line intraperitoneal cisplatin-paclitaxel and iFirst-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithntravenous ifosfamide in Stage IIIc ovarian epithelial cancer. elial cancer. Eur J Gynaecol OncolEur J Gynaecol Oncol. 2004;25(3):3. 2004;25(3):327-3227-32. .
![Page 38: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/38.jpg)
CHEMOTHERAPY CHEMOTHERAPY
First-line chemotherapy has been built on 2 First-line chemotherapy has been built on 2 premises supported by retrospective analyses premises supported by retrospective analyses and consecutive clinical trials by cooperative and consecutive clinical trials by cooperative groups: groups:
1. 1. PLATINUMPLATINUM COMPOUNDS, UP TO AN COMPOUNDS, UP TO AN “OPTIMAL DOSE-INTENSITY,” REPRESENT “OPTIMAL DOSE-INTENSITY,” REPRESENT THE CORE OF THE TREATMENT (E.G., THE CORE OF THE TREATMENT (E.G., PLATINUM-BASED CHEMOTHERAPY). PLATINUM-BASED CHEMOTHERAPY).
2. 2. CISPLATIN AND CARBOPLATINCISPLATIN AND CARBOPLATIN YIELD YIELD EQUIVALENT RESULTS EQUIVALENT RESULTS
![Page 39: Ovarian Cancer III](https://reader036.vdocuments.net/reader036/viewer/2022062304/56813c28550346895da5a423/html5/thumbnails/39.jpg)
RadiotherapyRadiotherapy
Consolidation with radiation therapy did Consolidation with radiation therapy did not yield not yield improved resultsimproved results in randomized trials following pl in randomized trials following platinum-based chemotherapy.atinum-based chemotherapy.
Fuks Z, Rizel S, Biran S: Chemotherapeutic and Fuks Z, Rizel S, Biran S: Chemotherapeutic and surgical induction of pathological complete remissurgical induction of pathological complete remission and whole abdominal irradiation for consolidsion and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovaration does not enhance the cure of stage III ovarian carcinoma. ian carcinoma. J Clin OncolJ Clin Oncol 6 (3): 509-16, 1988 6 (3): 509-16, 1988